(AYTU), Gilead Sciences, Inc. (NASDAQ:GILD) - Merger Thursday: Gilead Buys German Drug Company, Aytu-Neos All-Stock Deal, Boehringer Picks Up NBE-Therapeutics
Neos Therapeutics Inc (NASDAQ: NEOS) in an all-stock merger transaction. The boards of both companies have approved the deal. Upon the closing of the merger, Neos shareholders will receive 0.1088 shares of Aytu for each share they hold in Neos, after taking into account the 1-for-10 reverse split of Aytu shares that took effect Dec. 8. The deal terms value Neos at $44.9 million. Neos shareholders will end up owning a 30% stake in Aytu. "The combined entity will have an increased footprint in the prescription pediatric market, an established, growing multi-brand ADHD portfolio addressing the...
Source: benzinga.com